Effectiveness of anti-CGRP monoclonal antibodies in the preventive treatment of migraine: A prospective study of 63 patients.

[1]  Carlo Baraldi,et al.  Predictors of response to erenumab after 12 months of treatment , 2021, Brain and behavior.

[2]  A. Cano,et al.  Mab-Mig: Registry of the Spanish Neurological Society of Erenumab for Migraine Prevention. Three-Months Results , 2021 .

[3]  S. Silberstein,et al.  Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial , 2021, European journal of neurology.

[4]  S. Sacco,et al.  Early outcomes of migraine after erenumab discontinuation: data from a real-life setting , 2021, Neurological Sciences.

[5]  E. Loder,et al.  Real-world effectiveness and tolerability of erenumab: A retrospective cohort study , 2020, Cephalalgia : an international journal of headache.

[6]  A. Andreou,et al.  A prospective real-world analysis of erenumab in refractory chronic migraine , 2020, The Journal of Headache and Pain.

[7]  A. Andreou,et al.  The role of erenumab in the treatment of migraine , 2020, Therapeutic advances in neurological disorders.

[8]  S. Sacco,et al.  Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy , 2020, The Journal of Headache and Pain.

[9]  A. Padovani,et al.  Response Predictors in Chronic Migraine: Medication Overuse and Depressive Symptoms Negatively Impact Onabotulinumtoxin-A Treatment , 2019, Frontiers in Neurology.

[10]  U. Reuter,et al.  Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination , 2019, The Journal of Headache and Pain.

[11]  R. Lipton,et al.  Erenumab in chronic migraine , 2019, Neurology.

[12]  S. Sacco,et al.  European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention , 2019, The Journal of Headache and Pain.

[13]  M. Ferrari,et al.  Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study , 2018, The Lancet.

[14]  D. Dodick,et al.  ARISE: A Phase 3 randomized trial of erenumab for episodic migraine , 2018, Cephalalgia : an international journal of headache.

[15]  P. Goadsby,et al.  A Controlled Trial of Erenumab for Episodic Migraine , 2017, The New England journal of medicine.

[16]  T. Vos,et al.  Global, regional, and national incidence and prevalence, and years lived with disability for 328 diseases and injuries in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2017 .

[17]  S. Silberstein,et al.  Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial , 2017, The Lancet Neurology.

[18]  D. Dodick,et al.  Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis , 2016, Cephalalgia : an international journal of headache.

[19]  P. Martínez-Camblor,et al.  Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine , 2013, Neurology.

[20]  M. Brin,et al.  OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double‐Blind, Randomized, Placebo‐Controlled Phases of the PREEMPT Clinical Program , 2010, Headache.

[21]  H. Diener,et al.  OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial , 2010, Cephalalgia : an international journal of headache.

[22]  I. Hernando de la Bárcena,et al.  Experiencia clínica con erenumab durante el primer año de tratamiento , 2022, Revista de neurología (Ed. impresa).

[23]  M. Arnold.  Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition , 2018, Cephalalgia : an international journal of headache.

[24]  M. Gallego,et al.  OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study , 2018, European journal of neurology.